August 21, 2018 07:19 AM EDT
Discovery

Cam­bridge in­ves­ti­ga­tors ze­ro in on a new, niche drug tar­get for lung can­cer

Amber Tong

Lung can­cer has one of the poor­est sur­vival rates in on­col­o­gy. A group of re­searchers at the Uni­ver­si­ty of Cam­bridge wants to change that. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Af­ter re­search piv­ot, Bio­gen beefs up pipeline with Stoke's late-stage Dravet can­di­date

Ex­clu­sive: Atom­wise, a once high-fly­ing AI start­up, taps biotech vet as CEO to lead pared-down com­pa­ny

Pain biotech Lati­go eyes up to $150M raise fol­low­ing Ver­tex's land­mark FDA nod

As part of turn­around, Sol­id Bio re­ports promis­ing ini­tial da­ta for Duchenne gene ther­a­py

Ar­cus touts ear­ly kid­ney can­cer da­ta as Gilead de­clines op­tion

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times